NEA Management Company
Latest statistics and disclosures from NEA Management Company's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RYTM, ACLX, VRNA, COUR, TRVI, and represent 57.95% of NEA Management Company's stock portfolio.
- Added to shares of these 2 stocks: X4 Pharmaceuticals (+$5.9M), Imagenebio.
- Started 1 new stock position in Imagenebio.
- Reduced shares in these 8 stocks: ACLX (-$58M), CRSP (-$34M), INZY (-$9.8M), CELC (-$7.4M), ADAP, VRNA, IKNA, UP.
- Sold out of its positions in ADAP, IKNA, INZY, UP.
- NEA Management Company was a net seller of stock by $-109M.
- NEA Management Company has $1.8B in assets under management (AUM), dropping by 37.17%.
- Central Index Key (CIK): 0001512848
Tip: Access up to 7 years of quarterly data
Positions held by NEA Management Company consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for NEA Management Company
NEA Management Company holds 29 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals (RYTM) | 16.1 | $294M | 2.9M | 100.99 |
|
|
| Arcellx Common Stock (ACLX) | 13.7 | $250M | -18% | 3.0M | 82.10 |
|
| Verona Pharma Sponsered Ads (VRNA) | 13.2 | $240M | 2.3M | 106.71 |
|
|
| Coursera (COUR) | 8.3 | $151M | 13M | 11.71 |
|
|
| Trevi Therapeutics (TRVI) | 6.6 | $121M | 13M | 9.15 |
|
|
| Celcuity (CELC) | 5.8 | $106M | -6% | 2.1M | 49.40 |
|
| Savara (SVRA) | 4.8 | $87M | 25M | 3.57 |
|
|
| Crispr Therapeutics Namen Akt (CRSP) | 3.8 | $69M | -33% | 1.1M | 64.81 |
|
| Mbx Biosciences (MBX) | 3.5 | $63M | 3.6M | 17.50 |
|
|
| Zenas Biopharma (ZBIO) | 3.3 | $61M | 2.7M | 22.20 |
|
|
| Monte Rosa Therapeutics (GLUE) | 3.1 | $57M | 7.7M | 7.41 |
|
|
| Korro Bio (KRRO) | 2.9 | $52M | 1.1M | 47.89 |
|
|
| Oric Pharmaceuticals (ORIC) | 2.7 | $49M | 4.1M | 12.00 |
|
|
| Gossamer Bio (GOSS) | 2.6 | $48M | 18M | 2.63 |
|
|
| Aurinia Pharmaceuticals (AUPH) | 2.4 | $44M | 4.0M | 11.05 |
|
|
| Phathom Pharmaceuticals (PHAT) | 1.3 | $23M | 2.0M | 11.77 |
|
|
| Neuehealth Com New | 1.0 | $18M | 2.7M | 6.67 |
|
|
| Black Diamond Therapeutics (BDTX) | 0.9 | $17M | 4.4M | 3.79 |
|
|
| CVRX (CVRX) | 0.9 | $16M | 2.0M | 8.07 |
|
|
| Champions Oncology Com New (CSBR) | 0.6 | $11M | 1.7M | 6.47 |
|
|
| Inventiva Sa Ads (IVA) | 0.5 | $8.3M | 1.5M | 5.69 |
|
|
| Omada Health (OMDA) | 0.4 | $8.1M | 364k | 22.11 |
|
|
| X4 Pharmaceuticals | 0.4 | $7.6M | +347% | 2.2M | 3.42 |
|
| Nkarta (NKTX) | 0.4 | $7.4M | 3.6M | 2.07 |
|
|
| Senti Biosciences Com New (SNTI) | 0.3 | $5.3M | 3.8M | 1.41 |
|
|
| Synlogic Com New (SYBX) | 0.3 | $4.9M | 2.9M | 1.67 |
|
|
| Marker Therapeutics Com New (MRKR) | 0.1 | $1.5M | 1.6M | 0.89 |
|
|
| Onkure Therapeutics Com Cl A (OKUR) | 0.1 | $1.3M | 479k | 2.75 |
|
|
| Imagenebio | 0.0 | $408k | NEW | 50k | 8.15 |
|
Past Filings by NEA Management Company
SEC 13F filings are viewable for NEA Management Company going back to 2010
- NEA Management Company 2025 Q3 filed Nov. 14, 2025
- NEA Management Company 2025 Q2 filed Aug. 14, 2025
- NEA Management Company 2025 Q1 filed May 14, 2025
- NEA Management Company 2024 Q4 filed Feb. 14, 2025
- NEA Management Company 2024 Q3 filed Nov. 14, 2024
- NEA Management Company 2024 Q2 filed Aug. 14, 2024
- NEA Management Company 2024 Q1 filed May 15, 2024
- NEA Management Company 2023 Q4 filed Feb. 14, 2024
- NEA Management Company 2023 Q3 filed Nov. 14, 2023
- NEA Management Company 2023 Q2 filed Aug. 11, 2023
- NEA Management Company 2023 Q1 filed May 15, 2023
- NEA Management Company 2022 Q4 filed Feb. 10, 2023
- NEA Management Company 2022 Q3 filed Nov. 14, 2022
- NEA Management Company 2022 Q2 filed Aug. 15, 2022
- NEA Management Company 2022 Q1 filed May 16, 2022
- NEA Management Company 2021 Q4 filed Feb. 14, 2022